

Q3 FY 02/15

results supplementary material

These materials contain our earnings outlook. While our earnings outlook and views are based on internal and other reliable data, they do not constitute a guarantee of our future earnings. Therefore, sales and profits may differ from the figures outlined in this material.

The figures in these materials are rounded to the nearest million yen.

Jan. 9th, 2015

Hisamitsu Pharmaceutical Co., Inc.
(Security code number: 4530)

Consolidated Financial Statement

Jan. 9th, 2015

<Balance sheet> (Unit: ¥mn)	2011.05 Q1	2011.08 Q2	2011.11 Q3	2012.02 Q4	2012.05 Q1	2012.08 Q2	2012.11 Q3	2013.02 Q4	2013.05 Q1	2013.08 Q2	2013.11 Q3	2014.02 Q4	2014.05 Q1	2014.08 Q2	2014.11 Q3	As a % of total
Current assets	85,967	88,915	90,979	87,455	94,196	101,055	102,248	107,719	117,319	136,389	137,134	139,107	141,500	153,646	161,675	59.3%
Cash & deposits	25,158	22,293	23,545	27,789	31,490	31,767	31,287	41,157	45,338	53,481	54,033	66,307	63,541	71,030	66,942	
Notes and accounts receivable	37,098	38,419	38,665	33,635	36,059	39,498	39,307	36,986	39,137	46,737	45,643	37,092	41,788	45,517	44,345	
Marketable securities	3,626	6,475	4,730	7,083	6,367	9,054	9,015	12,338	12,948	15,054	14,397	15,453	15,281	15,061	22,692	
Inventory	12,506	12,443	13,324	12,551	13,933	12,698	13,399	13,329	14,237	13,995	14,201	15,195	14,763	14,334	14,970	
Deferred tax assets	3,869	3,668	3,516	2,896	3,045	2,898	2,865	2,281	2,322	2,410	2,471	2,921	2,760	2,698	2,712	
Other current assets	3,926	5,846	7,445	3,702	3,510	5,361	6,597	1,838	3,556	4,987	6,671	2,389	3,648	5,329	10,379	
Bad debt provision	-218	-230	-247	-202	-211	-223	-222	-211	-225	-283	-285	-255	-292	-331	-373	
Fixed assets	105,908	105,432	103,007	105,382	103,606	102,572	101,591	106,421	108,749	108,632	110,784	112,745	110,082	113,294	111,032	40.7%
Tangible fixed assets	44,365	43,993	43,147	43,357	43,381	42,845	42,782	43,219	43,257	43,334	42,985	43,330	43,576	43,326	44,049	
Buildings and structures	19,128	18,715	18,627	19,385	19,234	18,677	18,198	17,643	18,139	17,862	17,886	17,735	17,332	17,387	17,294	
Machinery and transport equipment	7,327	7,394	7,016	6,972	7,705	7,120	6,967	6,094	6,463	6,124	6,595	6,159	6,635	6,661	6,534	
Tools, instruments, etc.	2,590	2,539	2,386	2,470	2,372	2,237	2,139	2,354	2,378	2,360	2,388	2,320	2,242	2,223	2,245	
Land	12,444	12,421	12,353	12,364	12,422	12,373	12,355	12,462	12,557	12,601	12,591	12,677	12,652	12,636	12,722	
Construction in progress	2,420	2,496	2,352	1,772	1,275	2,088	2,774	4,518	3,587	4,268	3,404	4,321	4,609	4,320	5,171	
Lease assets	452	427	411	390	370	347	349	145	133	119	118	116	107	98	86	
Intangible fixed assets	18,017	18,059	16,982	16,548	16,352	15,399	14,558	17,163	17,612	17,421	16,638	16,812	16,104	15,207	16,129	
Investments, etc.	43,526	43,380	42,877	45,477	43,872	44,327	44,250	46,038	47,879	47,876	51,160	52,602	50,401	54,760	50,854	
Investment securities	29,564	29,611	29,208	34,549	33,339	34,319	34,598	36,685	38,861	39,325	42,369	42,947	41,576	45,207	41,970	
Long-term loans	126	121	118	123	120	115	110	81	80	69	69	66	64	61	60	
Deferred tax assets	4,056	3,979	4,053	1,402	1,674	1,301	1,135	460	81	224	544	1,239	1,420	1,555	1,696	
Other	9,909	9,892	9,724	9,630	8,967	8,819	8,635	9,028	9,076	8,471	8,396	8,565	7,555	8,150	7,341	
Bad debt provision	-131	-226	-226	-228	-228	-228	-228	-218	-218	-218	-218	-218	-218	-216	-216	
Total assets	191,876	194,347	193,987	192,838	197,802	203,628	203,839	214,141	226,068	245,021	247,918	251,852	251,583	266,940	272,708	
Current liabilities	39,060	41,156	38,746	31,134	34,351	35,574	33,993	34,385	35,793	46,616	44,395	41,745	41,854	49,637	47,295	17.3%
Notes and accounts payable	12,774	14,342	13,313	11,932	14,258	13,464	12,338	12,991	10,198	10,196	8,372	8,987	9,024	11,971	10,274	
Electronically recorded obligations-operating	-	-	-	-	-	-	-	-	3,827	8,770	8,258	5,625	7,503	8,028	7,781	
Short-term borrowing	9,618	6,774	6,992	4,445	4,287	1,730	1,729	1,674	1,690	1,718	1,698	1,677	1,693	1,715	1,694	
Accrued expenses	4,961	5,861	5,557	6,177	5,729	5,923	5,053	7,035	5,300	6,715	5,437	6,656	5,964	7,159	5,736	
Unpaid expenses	1,752	361	1,818	466	1,831	392	1,916	538	1,967	494	2,074	707	2,140	617	2,157	
Unpaid tax, etc.	2,486	5,139	2,106	3,839	2,166	5,952	4,056	6,576	4,613	8,039	5,606	7,354	2,746	5,582	2,429	
Bonus reserves	502	1,493	836	1,550	527	1,312	879	1,714	637	1,510	1,023	1,942	691	1,629	1,235	
Reserve for returned goods unsold	204	228	235	198	269	276	265	229	198	226	226	180	170	178	181	
Other current liabilities	6,759	6,956	7,885	2,522	5,281	6,521	7,754	3,620	7,356	8,938	11,693	8,614	11,912	12,748	15,800	
Fixed liabilities	15,410	12,419	12,409	12,441	12,428	12,277	11,778	11,822	11,978	11,964	12,935	13,799	13,711	14,717	15,924	5.8%
Long-term borrowing	3,961	1,348	1,282	1,224	1,169	1,107	1,048	989	950	928	890	852	815	773	756	
Provision for pension and remuneration obligations	6,075	6,112	6,178	6,157	6,239	6,317	6,362	6,421	6,272	6,319	6,381	6,465	6,522	6,628	6,734	
Deferred tax liabilities	4,097	3,686	3,685	3,389	3,137	3,096	2,565	2,286	2,955	2,623	3,617	3,775	3,788	4,648	5,494	
Other fixed liabilities	1,275	1,272	1,262	1,669	1,881	1,755	1,800	2,124	1,801	2,090	2,045	2,704	2,582	2,664	2,936	
Total liabilities	54,470	53,576	51,156	43,575	46,779	47,852	45,772	46,207	47,771	58,581	57,331	55,544	55,565	64,355	63,220	23.2%
Owners' Equity	142,023	146,352	150,933	154,702	155,317	161,036	163,724	167,511	172,025	178,191	180,698	182,865	183,436	189,009	190,698	69.9%
Common stock	8,473	8,473	8,473	8,473	8,473	8,473	8,473	8,473	8,473	8,473	8,473	8,473	8,473	8,473	8,473	
Capital surplus	8,396	8,396	8,396	8,396	8,396	8,396	8,396	8,396	8,396	8,396	8,396	8,396	8,396	8,396	8,396	
Retained earnings	146,996	151,326	155,907	159,677	160,291	166,012	168,700	172,488	177,003	183,170	185,678	187,846	188,417	193,992	195,681	
Treasury stock	-21,842	-21,843	-21,843	-21,844	-21,844	-21,845	-21,845	-21,846	-21,848	-21,849	-21,850	-21,851	-21,852	-21,853	-21,853	
Net unrealized gain and translation adjustments	-5,672	-6,642	-9,141	-6,476	-5,341	-6,311	-6,696	-325	5,472	7,379	9,053	12,577	11,656	12,624	17,812	6.5%
Other marketable securities revaluation account	-1,618	-1,532	-1,887	47	-996	-387	-2	2,175	4,323	4,259	6,472	6,611	6,685	8,402	9,990	
Land revaluation account	3,189	3,189	3,189	3,459	3,459	3,459	3,459	3,459	3,459	3,459	3,459	3,459	3,459	3,459	3,459	
Forex adjustment account	-7,244	-8,299	-10,443	-9,983	-7,805	-9,383	-10,153	-5,961	-2,310	-340	-878	2,506	1,511	762	4,362	
Minority interest	1,054	1,061	1,039	1,036	1,047	1,050	1,039	747	798	870	836	865	924	951	977	0.4%
Total Net assets	137,405	140,771	142,831	149,263	151,023	155,775	158,067	167,933	178,296	186,440	190,587	196,308	196,017	202,585	209,487	76.8%
Liabilities and Net assets	191,876	194,347	193,987	192,838	197,802	203,628	203,839	214,141	226,068	245,021	247,918	251,852	251,583	266,940	272,708	

Consolidated Financial Statement

Jan. 9th, 2015

<Profit and Loss statement> (Unit: ¥mn)		2011.05	2011.08	2011.11	2012.02	2012.05	2012.08	2012.11	2013.02	2013.05	2013.08	2013.11	2014.02	2014.05	2014.08	2014.11	Cons- parent ratio	YoY
		Q1	Q1-Q2	Q1-Q3	Q1-Q4	Q1	Q1-Q2	Q1-Q3	Q1-Q4	Q1	Q1-Q2	Q1-Q3	Q1-Q4	Q1	Q1-Q2	Q1-Q3		
Sales		33,039	69,169	103,773	137,794	34,670	71,932	107,357	142,772	37,065	77,382	115,129	150,635	37,756	77,052	114,940	1.28	99.8%
CoGS		10,938	23,047	34,588	46,785	12,532	26,013	38,358	51,659	13,841	28,018	41,112	55,471	13,931	27,901	40,954		99.6%
	(as a % of sales)	33.1%	33.3%	33.3%	34.0%	36.1%	36.2%	35.7%	36.2%	37.3%	36.2%	35.7%	36.8%	36.9%	36.2%	35.6%		
Gross profits		22,101	46,112	69,184	91,008	22,138	45,918	68,999	91,112	23,224	49,363	74,016	95,163	23,825	49,150	73,986	1.22	100.0%
	(as a % of sales)	66.9%	66.7%	66.7%	66.0%	63.9%	63.8%	64.3%	63.8%	62.7%	63.8%	64.3%	63.2%	63.1%	63.8%	64.4%		
SG&A costs		15,301	32,897	48,356	65,070	16,825	32,669	48,226	65,786	18,152	36,900	55,529	76,040	19,234	38,795	58,348		105.1%
	(as a % of sales)	46.3%	47.6%	46.6%	47.2%	48.5%	45.4%	44.9%	46.1%	49.0%	47.7%	48.2%	50.5%	50.9%	50.3%	50.8%		
Sales promotion costs		2,826	6,396	9,131	12,601	2,953	6,065	9,140	12,549	3,463	7,098	10,776	15,290	4,790	9,248	13,361		124.0%
Advertising costs		2,105	5,035	7,277	9,565	3,093	5,498	7,522	10,086	3,428	6,638	9,482	11,950	2,493	5,800	9,288		98.0%
R&D spending		3,535	7,487	10,800	14,758	3,423	6,278	9,537	12,662	3,106	6,570	10,327	13,924	3,466	6,732	10,602		102.7%
Other SG&A expenses		6,836	13,979	21,148	28,146	7,356	14,826	22,027	30,489	8,155	16,594	24,943	34,876	8,485	17,015	25,097		100.6%
Operating profits		6,800	13,214	20,827	25,937	5,313	13,248	20,773	25,326	5,071	12,462	18,487	19,123	4,590	10,355	15,637	0.75	84.6%
	(as a % of sales)	20.6%	19.1%	20.1%	18.8%	15.3%	18.4%	19.3%	17.7%	13.7%	16.1%	16.1%	12.7%	12.2%	13.4%	13.6%		
Nonoperating income		1,074	2,959	4,860	7,875	1,374	3,371	5,360	7,800	1,667	4,439	7,095	9,872	2,110	5,269	7,067		99.6%
Interest received		14	32	49	71	16	33	49	67	14	36	54	84	15	38	55		101.9%
Dividends received		27	212	339	392	27	232	383	433	28	264	386	477	29	289	407		105.4%
Royalty income		38	67	98	127	33	62	93	122	31	48	60	74	11	23	37		61.7%
Foreign exchange gains		3	-	-	-	-	-	-	253	232	134	212	294	-	27	477		225.0%
Equity-method investment profits		915	2,427	4,085	6,881	1,209	2,869	4,588	6,540	1,269	3,693	6,056	8,456	1,959	4,675	5,705		94.2%
Other		76	218	287	402	87	173	245	382	91	262	324	484	93	214	383		118.2%
Nonoperating expenses		42	265	315	319	67	138	76	74	19	46	68	85	45	52	66		97.1%
Interest paid		24	52	72	92	14	27	35	38	11	17	26	34	11	18	26		100.0%
Foreign exchange losses		-	79	97	44	44	89	13	-	-	-	-	-	26	-	-		-
Other		17	132	145	182	8	21	27	36	7	28	41	49	7	33	39		95.1%
Recurring profits		7,833	15,908	25,372	33,494	6,621	16,481	26,056	33,051	6,720	16,856	25,513	28,910	6,656	15,572	22,637	1.03	88.7%
	(as a % of sales)	23.7%	23.0%	24.4%	24.3%	19.1%	22.9%	24.3%	23.2%	18.1%	21.8%	22.2%	19.2%	17.6%	20.2%	19.7%		
Extraordinary profits		4,615	4,615	7,999	8,260	-	1	1	501	5,084	5,087	5,088	5,108	4	20	851		16.7%
Public subsidies		4,611	4,611	4,611	4,611	-	-	-	-	-	-	-	-	-	-	-		-
Gain on sales of investment securities		-	-	-	-	-	1	1	1	84	87	88	108	-	-	-		-
Reversal of allowance for doubtful receivables		3	3	3	20	-	-	-	-	-	-	-	-	-	-	-		-
Other		-	-	3,384	3,628	-	-	-	500	5,000	5,000	5,000	5,000	4	20	851		17.0%
Extraordinary losses		7,259	7,919	8,223	9,375	389	456	469	1,561	2	95	47	291	10	10	16		34.0%
Losses on fixed asset disposal		7	107	110	189	2	78	151	208	2	33	47	291	10	10	16		34.0%
Losses on fixed asset reduction		4,611	4,611	4,611	4,611	-	-	-	-	-	-	-	-	-	-	-		-
Impairment loss		-	-	-	-	-	-	-	1,353	-	-	-	-	-	-	-		-
Valuation losses on investment securities		-	487	758	1,940	387	378	318	-	-	61	-	-	-	-	-		-
Loss due to disaster		2,639	2,712	2,742	2,584	-	-	-	-	-	-	-	-	-	-	-		-
Other		-	-	-	49	-	-	-	-	-	-	-	-	-	-	-		-
Pretax profits		5,189	12,604	25,149	32,379	6,232	16,025	25,589	31,991	11,801	21,849	30,554	33,727	6,649	15,582	23,472	1.06	76.8%
Tax, etc.		2,430	5,516	10,480	13,940	2,619	6,691	10,567	13,182	4,287	8,166	11,365	12,369	2,559	6,007	8,995		79.1%
Net profits		2,758	7,087	14,669	18,439	3,613	9,334	15,021	18,809	7,514	13,681	19,188	21,357	3,998	9,574	14,476	1.02	75.4%
	(as a % of sales)	8.3%	10.2%	14.1%	13.4%	10.4%	13.0%	14.0%	13.2%	20.3%	17.7%	16.7%	14.2%	10.6%	12.4%	12.6%		
Capex			3,168		5,744		1,940		5,882		1,610		3,968		2,730			
	(as a % of sales)		4.6%		4.2%		2.7%		4.1%		2.1%		2.6%		3.5%			
Depreciation			2,569		5,882		2,901		5,814		2,665		5,534		2,550			
	(as a % of sales)		3.7%		4.3%		4.0%		4.1%		3.4%		3.7%		3.3%			
Goodwill amortization			453		1,332		888		1,780		959		1,958		998			
Number of employees			2,751		2,718		2,826		2,826		2,911		2,949		2,965			

Non-consolidated Financial Statement

Jna. 9th, 2015

<Balance sheet> (Unit: ¥mn)	2011.05 Q1	2011.08 Q2	2011.11 Q3	2012.02 Q4	2012.05 Q1	2012.08 Q2	2012.11 Q3	2013.02 Q4	2013.05 Q1	2013.08 Q2	2013.11 Q3	2014.02 Q4	2014.05 Q1	2014.08 Q2	2014.11 Q3	As a % of total
Current assets	64,272	67,263	70,487	66,865	70,650	76,294	79,278	81,419	87,008	102,227	103,603	101,484	103,899	113,419	114,147	47.4%
Cash & deposits	14,772	14,101	15,703	20,031	21,734	24,227	25,105	34,190	36,652	42,740	44,003	54,654	51,586	55,884	55,565	
Notes and accounts receivable	34,463	36,578	36,436	31,970	33,195	36,913	37,050	34,743	36,297	44,638	42,928	33,309	37,928	41,289	39,702	
Marketable securities	500	500	-	2,000	1,000	-	-	-	-	-	-	-	-	-	-	
Inventory	9,839	9,527	10,177	9,617	10,729	9,493	10,043	10,136	10,743	10,032	10,288	11,029	10,574	10,298	10,682	
Deferred tax assets	2,946	2,946	2,946	2,370	2,370	2,370	2,370	1,661	1,661	1,661	1,661	1,763	1,763	1,763	1,763	
Other current assets	1,942	3,812	5,426	1,054	1,804	3,493	4,913	875	1,856	3,400	4,958	912	2,254	4,407	6,648	
Bad debt provision	-191	-202	-202	-178	-185	-204	-205	-193	-201	-245	-236	-185	-210	-227	-219	
Fixed assets	116,735	116,782	116,233	117,653	115,519	116,280	115,818	119,032	120,654	119,168	122,044	122,012	121,354	125,215	126,423	52.6%
Tangible fixed assets	31,911	31,157	30,671	30,794	30,465	30,260	29,748	30,159	29,686	29,443	29,074	29,059	29,479	29,478	29,442	
Buildings and structures	11,935	11,553	11,274	12,062	11,745	11,383	11,055	10,955	11,060	10,764	10,891	10,645	10,383	10,561	10,339	
Machinery and transport equipment	5,503	5,074	4,634	4,668	5,255	4,823	4,728	4,355	4,586	4,217	3,870	3,513	3,921	4,030	3,719	
Tools, instruments, etc.	1,897	1,860	1,763	1,737	1,632	1,545	1,465	1,676	1,653	1,656	1,731	1,692	1,641	1,631	1,678	
Land	10,949	10,949	10,949	10,949	10,949	10,949	10,949	10,949	10,949	10,949	10,949	10,949	10,949	10,949	10,949	
Construction in progress	1,574	1,671	2,005	1,336	845	1,525	1,520	2,190	1,407	1,832	1,610	2,239	2,568	2,292	2,743	
Lease assets	51	47	44	40	36	33	29	34	30	26	22	19	16	14	16	
Intangible fixed assets	7,798	8,486	8,220	7,953	7,687	7,421	7,155	6,889	6,623	6,356	6,140	5,854	5,583	5,312	5,041	
Investments, etc.	77,025	77,137	77,342	78,905	77,366	78,598	78,914	81,983	84,345	83,367	86,829	87,098	86,291	90,424	91,939	
Investment securities	16,018	15,914	16,175	19,085	17,902	19,190	19,824	23,606	26,706	26,715	30,204	30,729	30,932	34,456	36,573	
Advances to and shares in related companies	47,141	47,141	47,141	48,477	48,477	48,722	48,722	48,148	48,148	48,148	48,148	48,148	48,148	48,148	48,148	
Long-term loans	337	784	780	942	934	1,120	1,123	1,360	1,380	1,362	1,432	1,265	1,162	1,663	2,014	
Deferred tax assets	4,251	4,198	4,302	1,569	1,916	1,607	1,482	783	-	-	-	-	-	-	-	
Other investments, etc.	9,624	9,529	9,371	9,256	8,564	8,377	8,177	8,502	8,533	7,551	7,453	7,375	6,474	6,572	5,618	
Bad debt provision	-348	-430	-429	-425	-428	-419	-415	-419	-425	-413	-410	-419	-426	-418	-418	
Total assets	181,007	184,044	186,721	184,518	186,169	192,575	195,096	200,451	207,663	221,395	225,647	223,497	225,254	238,635	240,571	
Current liabilities	29,512	30,685	29,354	22,866	25,077	25,566	25,216	24,051	24,318	32,324	30,832	25,089	25,788	31,547	29,395	12.2%
Notes and accounts payable	8,555	9,377	9,251	8,485	9,519	8,937	9,066	9,313	5,715	3,700	3,729	4,017	3,475	3,635	3,901	
Electronically recorded obligations-operating short-term debt	-	-	-	-	-	-	-	-	3,827	8,770	8,258	5,625	7,503	8,028	7,781	
Accrued expenses	8,100	5,100	5,100	2,550	2,550	-	-	-	-	-	-	-	-	-	-	
Unpaid expenses	5,755	6,501	6,045	6,603	6,905	6,269	5,413	7,036	6,033	7,079	5,941	6,939	6,783	8,008	6,044	
Unpaid tax, etc.	1,608	215	1,655	219	1,646	213	1,693	218	1,711	240	1,753	240	1,765	254	1,787	
Bonus reserves	1,888	4,706	1,784	3,642	2,030	5,745	3,756	6,198	4,384	7,661	4,888	6,699	2,442	5,219	2,028	
Reserve for returned goods unsold	222	942	232	892	248	949	251	916	257	984	245	955	251	999	223	
Other current liabilities	204	228	235	198	269	276	265	229	198	226	226	180	170	178	181	
Fixed liabilities	3,177	3,613	5,050	274	1,906	3,174	4,769	135	2,188	3,657	5,786	429	3,392	5,217	7,443	
Long-term borrowing	10,632	8,106	8,173	7,881	7,949	8,018	8,059	8,111	8,178	8,138	9,213	9,547	9,606	10,506	11,398	4.7%
Provision for pension and remuneration obligations	2,550	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Deferred tax liabilities related to revaluation	5,878	5,905	5,975	5,958	6,030	6,102	6,147	6,195	6,032	6,076	6,147	6,220	6,273	6,373	6,471	
Other fixed liabilities	2,164	2,164	2,164	1,894	1,894	1,894	1,894	1,894	1,894	1,894	1,894	1,894	1,894	1,894	1,894	
Total liabilities	39	36	32	29	25	21	18	21	251	166	1,171	1,433	1,439	2,238	3,032	
Owners' Equity	151,495	153,359	157,367	161,652	161,092	167,009	170,380	176,400	183,345	189,071	194,815	198,408	199,466	207,088	211,176	77.5%
Common stock	40,145	38,791	37,527	30,748	33,026	33,584	33,276	32,162	32,496	40,462	40,045	34,636	35,395	42,053	40,793	
Capital surplus	139,321	143,619	147,908	150,299	150,707	155,942	158,391	162,767	167,565	173,386	175,853	179,000	179,909	184,917	186,552	
Capital reserves	8,473	8,473	8,473	8,473	8,473	8,473	8,473	8,473	8,473	8,473	8,473	8,473	8,473	8,473	8,473	
Other capital surplus	8,241	8,241	8,241	8,241	8,241	8,241	8,241	8,241	8,241	8,241	8,241	8,241	8,241	8,241	8,241	
Retained earnings	2,118	2,118	2,118	2,118	2,118	2,118	2,118	2,118	2,118	2,118	2,118	2,118	2,118	2,118	2,118	
Voluntary reserve	6,123	6,123	6,123	6,123	6,123	6,123	6,123	6,123	6,123	6,123	6,123	6,123	6,123	6,123	6,123	
Unappropriated profit for the year (net profit)	144,421	148,720	153,009	155,400	155,809	161,044	163,493	167,869	172,669	178,491	180,959	184,107	185,016	190,024	191,660	
Treasury stock	135,000	135,000	135,000	135,000	146,000	146,000	146,000	146,000	158,000	158,000	158,000	158,000	173,000	173,000	173,000	
Net unrealized gain and translation adjustments	9,421	13,720	18,009	20,400	9,809	15,044	17,493	21,869	14,669	20,491	22,959	26,107	12,016	17,024	18,660	
Marketable securities revaluation account	2,783	7,081	14,370	16,761	3,408	8,643	14,091	18,467	7,798	13,620	19,088	22,235	4,336	9,345	14,194	
Revaluation account	-21,816	-21,817	-21,817	-21,817	-21,817	-21,817	-21,818	-21,818	-21,819	-21,820	-21,821	-21,821	-21,822	-21,823	-21,823	
Total Net assets	151,495	153,359	157,367	161,652	161,092	167,009	170,380	176,400	183,345	189,071	194,815	198,408	199,466	207,088	211,176	83.0%
Liabilities and Net assets	181,007	184,044	186,721	184,518	186,169	192,575	195,096	200,451	207,663	221,395	225,647	223,497	225,254	238,635	240,571	

Non-consolidated Financial Statement

Jan. 9th, 2015

<Profit and Loss statement> (Unit: ¥mn)	2011.05 Q1	2011.08 Q1-Q2	2011.11 Q1-Q3	2012.02 Q1-Q4	2012.05 Q1	2012.08 Q1-Q2	2012.11 Q1-Q3	2013.02 Q1-Q4	2013.05 Q1	2013.08 Q1-Q2	2013.11 Q1-Q3	2014.02 Q1-Q4	2014.05 Q1	2014.08 Q1-Q2	2014.11 Q1-Q3	YoY
Sales	28,303	60,034	90,221	119,326	29,470	61,779	92,447	122,433	30,848	64,293	95,335	123,977	29,968	61,113	90,012	94.4%
Rx Business	23,088	47,686	72,832	95,036	24,659	49,778	74,822	98,002	23,485	49,696	74,266	96,251	22,615	46,192	68,547	92.3%
OTC Business	4,408	10,083	13,745	18,424	3,790	9,335	13,605	18,037	5,887	10,889	15,573	20,049	6,005	11,534	16,172	103.8%
Intl Business	806	2,264	3,642	5,865	1,021	2,665	4,018	6,393	1,474	3,708	5,495	7,676	1,347	3,386	5,292	96.3%
CoGS	8,544	18,285	27,426	37,009	9,687	20,513	30,299	40,610	10,591	21,484	31,114	41,168	9,955	20,013	29,256	94.0%
(as a % of sales)	30.2%	30.5%	30.4%	31.0%	32.9%	33.2%	32.8%	33.2%	34.3%	33.4%	32.6%	33.2%	33.2%	32.7%	32.5%	
Gross profits	19,758	41,749	62,794	82,316	19,783	41,265	62,148	81,822	20,256	42,809	64,221	82,808	20,012	41,100	60,756	94.6%
(as a % of sales)	69.8%	69.5%	69.6%	69.0%	67.1%	66.8%	67.2%	66.8%	65.7%	66.6%	67.4%	66.8%	66.8%	67.3%	67.5%	
SG&A costs	12,573	26,997	39,335	52,335	13,829	26,830	39,006	51,815	13,469	27,214	40,460	54,259	13,425	27,215	40,010	98.9%
(as a % of sales)	44.4%	45.0%	43.6%	43.9%	46.9%	43.4%	42.2%	42.3%	43.7%	42.3%	42.4%	43.8%	44.8%	44.5%	44.4%	
Sales promotion costs	2,534	5,753	8,174	11,163	2,626	5,375	7,985	10,789	2,837	5,727	8,615	11,900	2,867	5,654	8,170	94.8%
Advertising costs	2,064	4,923	7,105	8,728	2,895	5,138	6,875	8,853	2,710	5,234	7,147	8,873	2,248	5,044	6,860	96.0%
R&D spending	2,805	5,857	8,065	10,628	2,639	4,993	7,336	9,546	2,216	4,679	7,482	10,197	2,716	5,021	8,092	108.2%
Other SG&A expenses	5,170	10,464	15,991	21,816	5,669	11,324	16,810	22,627	5,706	11,574	17,216	23,289	5,594	11,496	16,888	98.1%
Operating profits	7,185	14,751	23,458	29,980	5,954	14,435	23,141	30,006	6,786	15,594	23,761	28,549	6,587	13,885	20,745	87.3%
(as a % of sales)	25.4%	24.6%	26.0%	25.1%	20.2%	23.4%	25.0%	24.5%	22.0%	24.3%	24.9%	23.0%	22.0%	22.7%	23.0%	
Nonoperating income	156	516	719	854	168	488	745	1,034	374	717	1,025	1,124	194	678	1,364	133.1%
Interest received	3	8	13	19	4	10	14	22	5	14	18	28	5	16	23	127.8%
Dividends received	48	277	404	457	57	298	449	499	65	364	486	578	69	446	563	115.8%
Royalty income	56	85	131	160	52	82	133	162	58	87	128	142	58	69	125	97.7%
Foreign exchange gains	-	-	-	-	-	-	16	190	186	92	203	162	-	41	440	216.7%
Other	48	144	169	215	54	97	131	159	57	158	186	213	60	103	210	112.9%
Nonoperating expenses	37	238	262	206	57	89	30	47	11	14	21	27	37	30	37	176.2%
Interest paid	16	33	43	53	5	9	9	9	-	-	-	-	-	-	-	-
Foreign exchange losses	7	94	101	28	43	64	-	-	-	-	-	-	23	-	-	-
Other	13	111	117	125	8	15	21	37	11	14	21	27	12	30	37	176.2%
Recurring profits	7,304	15,029	23,915	30,628	6,065	14,834	23,855	30,999	7,149	16,298	24,765	29,645	6,744	14,533	22,072	89.1%
(as a % of sales)	25.8%	25.0%	26.5%	25.7%	20.6%	24.0%	25.8%	25.3%	23.2%	25.3%	26.0%	23.9%	22.5%	23.8%	24.5%	
Extraordinary profits	5	13	3,399	3,662	-	1	1	501	5,000	5,000	5,000	5,018	-	-	-	-
Gain on sales of investment securities	-	-	34	34	-	1	1	1	-	-	-	18	-	-	-	-
Reversal of allowance for doubtful receivables	5	13	15	34	-	-	-	-	-	-	-	-	-	-	-	-
Other	-	-	3,349	3,593	-	-	-	500	5,000	5,000	5,000	5,000	-	-	-	-
Extraordinary losses	2,643	3,296	3,597	4,602	387	453	418	715	-	69	9	52	1	7	9	100.0%
Losses on fixed asset disposal	3	96	96	123	-	74	99	141	-	8	9	52	1	7	9	100.0%
Valuation losses on investment securities	-	487	758	1,847	387	378	318	573	-	61	-	-	-	-	-	-
Loss due to disaster	2,639	2,712	2,742	2,584	-	-	-	-	-	-	-	-	-	-	-	-
Other	-	-	-	47	-	-	-	-	-	-	-	-	-	-	-	-
Pretax profits	4,666	11,746	23,717	29,688	5,678	14,382	23,438	30,785	12,149	21,228	29,755	34,612	6,743	14,526	22,063	74.1%
Tax, etc.	1,883	4,665	9,347	11,189	2,270	5,738	9,346	11,776	4,351	7,607	10,667	12,417	2,407	5,181	7,869	73.8%
Net profits	2,783	7,081	14,370	16,761	3,408	8,643	14,091	18,467	7,798	13,620	19,088	22,235	4,336	9,345	14,194	74.4%
(as a % of sales)	9.8%	11.8%	15.9%	14.0%	11.6%	14.0%	15.2%	15.1%	25.3%	21.2%	20.0%	17.9%	14.5%	15.3%	15.8%	
Capex		648		2,431		1,369		3,304		966		2,461			1,927	
(as a % of sales)		1.1%		2.0%		2.2%		2.7%		1.5%		2.0%			3.2%	
Depreciation		1,629		3,945		1,822		3,756		1,618		3,334			1,460	
(as a % of sales)		2.7%		3.3%		2.9%		3.1%		2.5%		2.7%			2.4%	
Goodwill amortization		88		621		532		1,064		532		1,084			542	
Number of employees		1,481		1,428		1,479		1,451		1,540		1,528			1,583	

(Unit: ¥mn)	2011.05 Q1	2011.08 Q1-Q2	2011.11 Q1-Q3	2012.02 Q1-Q4	2012.05 Q1	2012.08 Q1-Q2	2012.11 Q1-Q3	2013.02 Q1-Q4	2013.05 Q1	2013.08 Q1-Q2	2013.11 Q1-Q3	2014.02 Q1-Q4	2014.05 Q1	2014.08 Q1-Q2	2014.11 Q1-Q3	YoY
Fentos® Tape	624	1,368	2,280	3,272	883	1,699	2,734	3,792	836	1,757	2,867	3,944	746	1,973	3,338	116.4%
Norspan® Tape	-	44	152	320	257	588	937	1,330	439	903	1,355	1,834	498	1,039	1,530	112.9%
Neoxy® Tape	-	-	-	-	-	-	-	-	10	493	643	690	157	367	673	104.7%
Mohrus® Tape	18,437	37,667	57,705	75,368	19,514	39,390	59,205	77,678	18,515	38,939	58,292	75,732	17,794	35,665	52,599	90.2%
Mohrus® Pap	1,969	4,340	6,543	8,240	2,038	4,164	6,166	7,846	1,726	3,679	5,500	6,935	1,596	3,274	4,786	87.0%
Minivelle®	-	-	-	-	-	-	-	-	178	783	1,689	2,858	1,578	3,436	5,643	334.1%
Vivelle-Dot® products	793	1,730	2,594	3,442	1,014	1,948	2,819	3,822	1,073	2,547	3,422	4,251	806	1,795	3,106	90.8%
CombiPatch® products	147	360	591	735	238	394	662	789	278	478	846	1,042	221	365	954	112.8%
Brisdelle®	-	-	-	-	-	-	-	-	-	-	-	-12	105	297	595	-
Daytrana®	1,425	2,486	3,337	4,625	1,356	2,483	3,514	4,895	1,665	3,240	4,561	5,973	1,725	3,478	4,950	108.5%
Salonpas® products	2,463	6,069	9,360	13,466	2,739	6,743	10,223	14,240	3,593	8,312	12,753	17,149	4,371	9,685	14,318	112.3%
Salonip® products	744	1,959	2,924	4,042	752	2,178	3,239	4,290	990	2,389	3,531	4,568	1,104	2,567	3,808	107.8%
Air® Salonpas® products	418	1,259	1,601	1,922	447	1,241	1,607	1,911	495	1,277	1,695	2,038	514	1,235	1,703	100.5%
Feitas® products	938	2,080	2,767	3,566	601	1,745	2,671	3,455	777	1,602	2,939	3,543	848	2,247	3,283	111.7%
Butenolock® products	778	1,053	1,029	1,779	816	1,046	1,055	1,394	1,112	1,407	1,481	1,704	1,291	1,557	1,627	109.9%
Allegra® FX	-	-	-	-	-	-	200	970	1,183	1,186	1,323	2,512	723	774	988	74.7%

Earnings Forecasts

Jan. 9th, 2015

(#mn)

<Consolidated>	Feb 2014A			Cons-parent ratio
	Q1-Q4	YoY	Q1-Q2	
Sales	150,635	105.5%	77,382	1.22
CoGS	55,471	107.4%	28,108	
(CoGS ratio %)	36.8%	-	36.3%	
Gross profits	95,163	104.4%	49,363	
(as a % of sales)	63.2%	-	63.8%	
SG&A costs	76,040	115.6%	36,900	
(Sales promotion costs)	15,291	121.8%	7,099	
(Advertising costs)	11,950	118.5%	6,638	
(R&D spending)	13,924	110.0%	6,570	
(Other SG&A expenses)	34,875	114.4%	16,593	
Operating profits	19,123	75.5%	12,462	0.67
(as a % of sales)	12.7%	-	16.1%	
Nonoperating balance	9,787	126.7%	4,393	
Recurring profits	28,910	87.5%	16,856	0.98
(as a % of sales)	19.2%	-	21.8%	
Extraordinary balance	4,817	-	4,992	
Pretax profits	33,727	105.4%	21,849	
Provision for tax	12,369	93.8%	8,166	
(effective tax rate)	36.7%	-	37.3%	
Net profits	21,357	113.5%	13,681	0.96
(as a % of sales)	14.2%	-	17.7%	
Capex	3,968		1,610	
Depreciation	5,534		2,665	
Goodwill amortization	1,958		959	
Amortization of stocks of subsidiaries and affiliates	3,499		1,712	

<Non-Consolidated>

Sales	123,977	101.3%	64,293
Rx Business	96,251	98.2%	49,696
OTC Business	20,049	111.2%	10,889
Intl Business	7,676	120.1%	3,708
CoGS	41,168	101.4%	21,484
(CoGS ratio %)	33.2%	-	33.4%
Gross profits	82,808	101.2%	42,809
(as a % of sales)	66.8%	-	66.6%
SG&A costs	54,259	104.7%	27,214
(Sales promotion costs)	11,901	110.3%	5,727
(Advertising costs)	8,873	100.2%	5,234
(R&D spending)	10,197	106.8%	4,679
(Other SG&A expenses)	23,288	102.9%	11,573
Operating profits	28,549	95.1%	15,594
(as a % of sales)	23.0%	-	24.3%
Nonoperating balance	1,097	110.6%	703
Recurring profits	29,645	95.6%	16,298
(as a % of sales)	23.9%	-	25.3%
Extraordinary balance	4,966	-	4,931
Pretax profits	34,612	112.4%	21,228
Provision for tax	12,376	100.5%	7,607
(effective tax rate)	35.8%	-	35.8%
Net profits	22,235	120.4%	13,620
(as a % of sales)	17.9%	-	21.2%
Capex	2,461		966
Depreciation	3,334		1,618
Goodwill amortization	1,084		532

<By product>

Fentos® Tape	3,944	104.0%	1,757
Norspan® Tape	1,834	137.9%	903
Neoxy® Tape	690	-	493
Mohrus® Tape products	75,732	97.5%	38,939
Mohrus® Pap products	6,935	88.4%	3,679
Minivelle®	2,858	-	783
Vivelle-Dot® products	4,251	111.2%	2,547
CombiPatch® products	1,042	132.1%	478
Brisdelle®	-12	-	-
Daytrana®	5,973	122.0%	3,240
Salonpas® products	17,149	120.4%	8,312
Salonip® products	4,568	106.5%	2,389
Air® Salonpas® products	2,038	106.6%	1,277
Feitas® products	3,543	102.5%	1,602
Butenalock® products	1,704	122.2%	1,407
Allegra® FX	2,512	259.0%	1,186

(#mn)

Feb 2015E			
Q1-Q4	YoY	*1 Q1-Q2	Cons-parent ratio
161,900	107.5%	77,000	1.27
59,500	107.3%	27,900	
36.8%	-	36.2%	
102,400	107.6%	49,100	
63.2%	-	63.8%	
82,000	107.8%	38,800	
18,700	122.3%	9,300	
13,000	108.8%	5,800	
14,000	100.5%	6,700	
36,300	104.1%	17,000	
20,400	106.7%	10,300	0.75
12.6%	-	13.4%	
7,400	75.6%	5,200	
27,800	96.2%	15,500	1.00
17.2%	-	20.1%	
0	-	0	
27,800	82.4%	15,500	
9,800	79.2%	6,000	
35.3%	-	38.7%	
18,000	84.3%	9,500	0.99
11.1%	-	12.3%	
6,600		3,600	
6,000		2,900	
2,000		1,000	
1,100		900	

*2 *2 *2

Sales	127,300	102.7%	61,100
Rx Business	97,700	101.5%	46,200
OTC Business	21,200	105.7%	11,500
Intl Business	8,400	109.4%	3,400
CoGS	44,000	106.9%	20,000
(CoGS ratio %)	34.6%	-	32.7%
Gross profits	83,300	100.6%	41,100
(as a % of sales)	65.4%	-	67.3%
SG&A costs	56,200	103.6%	27,200
(Sales promotion costs)	12,500	105.0%	5,700
(Advertising costs)	8,400	94.7%	5,000
(R&D spending)	10,300	101.0%	5,000
(Other SG&A expenses)	25,000	107.4%	11,500
Operating profits	27,100	94.9%	13,900
(as a % of sales)	21.3%	-	22.7%
Nonoperating balance	700	63.8%	600
Recurring profits	27,800	93.8%	14,500
(as a % of sales)	21.8%	-	23.7%
Extraordinary balance	0	-	0
Pretax profits	27,800	80.3%	14,500
Provision for tax	9,600	77.6%	5,250
(effective tax rate)	34.5%	-	36.2%
Net profits	18,200	81.9%	9,250
(as a % of sales)	14.3%	-	15.1%
Capex	4,500		2,300
Depreciation	3,400		1,700
Goodwill amortization	1,100		550

*2 *2 *2

Fentos® Tape	4,700	119.2%	1,950
Norspan® Tape	4,000	218.1%	1,050
Neoxy® Tape	1,550	224.6%	350
Mohrus® Tape products	74,050	97.8%	35,700
Mohrus® Pap products	6,100	88.0%	3,250
Minivelle®	8,400	293.9%	3,400
Vivelle-Dot® products	3,600	84.7%	1,800
CombiPatch® products	2,000	191.9%	350
Brisdelle®	1,300	-	300
Daytrana®	6,300	105.5%	3,450
Salonpas® products	19,750	115.2%	9,700
Salonip® products	4,950	108.4%	2,550
Air® Salonpas® products	2,100	103.0%	1,250
Feitas® products	4,100	118.0%	2,250
Butenalock® products	1,850	108.6%	1,550
Allegra® FX	2,000	79.6%	750

*1 Change of forecast as of Oct 2,2014.

*2 Change of forecast as of Oct 9,2014.